Deakin University
2 files

Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older

journal contribution
posted on 2019-08-01, 00:00 authored by Desmond Curran, Lidia Oostvogels, Thomas Heineman, Sean Matthews, Janet McElhaney, Shelly McNeil, Javier Diez-Domingo, Himal Lal, Charles Andrews, Eugene AthanEugene Athan, Johan Berglund, Laura Campora, Ferdinandus de Looze, Tiina Korhonen, Edward Leung, Myron Levin, Antonio Volpi, Robert W Johnson, ZOE-50/70 study group
Background: To determine the efficacy of a recombinant zoster vaccine (RZV) in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living (ADLs) and HZ impact on quality of life (QoL). Methods: The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of illness and HZ burden of interference with ADLs were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument; QoL by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled analysis of subjects ≥70 years of age from the trials combined. Results: The estimated vaccine efficacy (VE) in reducing HZ burden of illness as well as HZ burden of interference was >90% in both the ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, RZV reduced the maximal ZBPI worst-pain score in the pooled ZOE-70 analysis (p=0.032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p=0.049) and the pooled ZOE-70 analysis (p=0.043). In breakthrough HZ cases, trends for diminished loss of QoL compared to placebo-recipient HZ cases were observed, with differences up to 0.14 on the EQ-5D index at time points during the four weeks following HZ onset. Conclusions: RZV reduced the HZ burden of illness significantly, particularly due to its very high VE in preventing HZ. For breakthrough HZ cases, the results suggest that RZV mitigated severity of HZ-related pain, burden of interference with ADLs and recipients' utility loss.



Journals of gerontology: series A






1231 - 1238


Oxford University Press


Oxford, Eng.







Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2018, The Authors